Direct Ethanol Biomarker Testing: PETH
Answers From the Lab
Several major medical organizations recommend routine screening for unhealthy alcohol use. In this test specific episode of the "Answers From the Lab" podcast, Paul Jannetto, Ph.D., describes Mayo Clinic Laboratories' new direct biomarker test for alcohol consumption, PETH. This blood test has a much longer window of detection than existing urine tests for alcohol use.
"Alcohol is the most commonly abused drug in the world, and excessive alcohol use is the leading preventable cause of death in the United States," Dr. Jannetto says. "Routine screening and behavioral intervention for alcohol misuse is one of the most cost-effective clinical preventive services."
The preferred screening approach for ethanol — the chemical term for alcohol — measures certain substances that the body produces when ethanol is metabolized. The direct ethanol metabolites (i.e., ethyl glucuronide and ethyl sulfate) currently used for alcohol testing can be detected in urine for up to five days.
PETH measures a different alcohol metabolite, known as phosphatidylethanol (PEth), in whole blood. "This new biomarker gives a window of detection of approximately two to four weeks in blood. The window can be longer in individuals who chronically or excessively consume alcohol," Dr. Jannetto says.
Listen to learn more about how PETH provides enhanced screening for alcohol consumption.
Note: Podcasts will not playback on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.
This assay is designed to quantify two homologues of phosphatidylethanol (PEth) in whole blood collected in EDTA vacutainer tubes. The report is intended for use by physicians to verify abstinence or use of ethanol especially in liver transplant candidates/patients.
Analytic time: 2 days
Days performed: Monday through Friday (8 a.m.)
Patients with elevated LDL or "bad" cholesterol face even greater risk if their levels of small dense LDL cholesterol are also high. Vlad Vasile, M.D., Ph.D., and Leslie Donato, Ph.D., explain how Mayo Clinic Laboratories' sdLDL-c assay measures concentrations of the small dense LDL subtype, to better guide clinical care.
Identifying a precise genetic cause of hearing loss impacts clinical management. Nicole Boczek, Ph.D., and Melanie Meyer, M.S., CGC, explain how Mayo Clinic Laboratories' updated panel yields comprehensive results for optimal patient care.
In this test-specific episode of the "Answers From the Lab" podcast, Wei Shen, Ph.D., explains how Mayo Clinic Laboratories' new breast cancer panel provides rapid results to guide critical decisions about treatment and screening.